In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDItm for all indications matching the reference product Stelara® (ustekinumab) and has granted a provisional determination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback